C. Chouaïd

Hôpital Intercommunal de Créteil ORCID: 0000-0002-4290-5524

2

h-index

2

Publications

3,420

Citations

Publications

2 shown

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Naiyer A. Rizvi , Julien Mazières , David Planchard +27 more

2015 The Lancet Oncology 1406 citations

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares , Mikhail Dvorkin , Yuanbin Chen +97 more

2019 The Lancet 2014 citations

Frequent Co-Authors

Naiyer A. Rizvi

Columbia University Irving Medical Center

Julien Mazières

Université Toulouse III - Paul Sabatier

David Planchard

Institut Gustave Roussy

Thomas E. Stinchcombe

University of North Carolina at Chapel Hill

Grace K. Dy

Roswell Park Comprehensive Cancer Center

Scott Antonia

Moffitt Cancer Center

Researcher Info

h-index: 2
Publications: 2
Citations: 3,420
Institution: Hôpital Intercommunal de Créteil

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-4290-5524

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.